Navigation Links
Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
Date:3/11/2008

the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, VANTAS and SUPPRELIN LA; effectiveness of our sales force; competition and its effect on pricing, spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; risks associated with being a manufacturer of some of our products; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement policies and/or rates for SANCTURA, SANCTURA XR, VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR; product liability and insurance uncertainties; risks relating to the Redux-related litigation; need for additional funds and corporate partners, including for the development of our products; history of operating losses and expectation of future losses; uncertainties relating to controls over financial reporting; difficulties in managing our growth; valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; general worldwide economic conditions and related uncertainties; and other risks. Indevus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact:

Michael W. Rogers
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
2. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
3. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
4. Indevus Announces Allergan as New Partner for SANCTURA Brand
5. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
6. VIA Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
7. Bayer HealthCare Pharmaceuticals Introduces VistaTrak(TM) an Innovative Contrast Media Management System
8. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
9. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
10. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... -- Research and Markets has announced the ... 2014" report to their offering. ... professional and in-depth study on the current state of ... provides a basic overview of the industry including definitions, ... market analysis is provided for the international markets including ...
(Date:9/18/2014)... , Sept. 18, 2014  U.S. biotech company ... an exclusive license for technology developed by the ... expression in plants, including for applications in production of ... The technology was developed under the direction of ... Kultevat and former president of the Danforth Plant Science ...
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... previously announced concurrent but separate underwritten offerings of 10,000,000 ... the public of $2.00 per share, for expected gross ... Series A Convertible Preferred Stock at a price to ... proceeds of $20 million. Each share of Series A ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 OMICS ... the globe to participate in the ‘Open Access ... articles to OMICS Group Pharma Journals ... one of the fastest emerging Sciences, accelerating with ... healthcare services across the globe. The industry is ...
Breaking Biology Technology:Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Kultevat obtains license of gene switch technology 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3
... Eli Lilly and Company,(NYSE: LLY ) today announced ... as a Distinguished Lilly Scholar focusing on schizophrenia,and other ... Dr. Conley join our team here at,Lilly," said Jack ... well-known thought leader, clinician and scientist who brings,important experience ...
... REINACH, Switzerland, December 14 As reported,in September, ... at this,year,s Interscience Conference on Antimicrobial Agents and ... at ICAAC, that was,supported through an educational grant ... The symposium is entitled "Treatment of Methicillin-resistant,Staphylococcus ...
... Bradley,Pharmaceuticals, Inc. (NYSE: BDY ) today announced ... the topical treatment of,external genital (EGW) and perianal ... older. Veregen(TM) is the first new,prescription treatment for ... product from MediGene AG (Frankfurt: MDG) and has ...
Cached Biology Technology:Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar 2Arpida-Supported CME Symposium Available Online 2Arpida-Supported CME Symposium Available Online 3Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15% 2Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15% 3Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15% 4Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15% 5Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15% 6
(Date:9/17/2014)... A UT Arlington engineering professor and his doctoral student ... that can accumulate water collected from fog and dew., ... the world or deserts around the globe., Cheng Luo, ... Xin Heng, PhD candidate in the same College of ... Aug. 25 edition of ACS, (American Chemical Society) ...
(Date:9/17/2014)... 2014) A rare genetic disorder known as Jacobsen syndrome ... joint investigation by researchers at San Diego State University ... to suggesting better treatment options for people with Jacobsen ... genetic underpinnings of autism., Jacobsen syndrome affects approximately 1 ... Health. It occurs in a person when there is ...
(Date:9/17/2014)... shopping bags and their environmental impact recently scored a ... statewide ban on the bags, and Governor Jerry Brown ... industry is not yielding without a fight, according to ... the weekly newsmagazine of the American Chemical Society. , ... the anti-bag campaign logged its first small victory in ...
Breaking Biology News(10 mins):Shorebird's beak inspires UT Arlington research on water collection 2A link between Jacobsen syndrome and autism 2
... convey vital medical information, but the sight of a needle ... developed by a team of researchers in Israel, however, can ... in real-time, simply by shining a light through the skin. ... to provide high-resolution images of blood coursing through our veins ...
... differences in bacterial colonization of the infant gut in formula-fed ... genes involved in the infant,s immune system. The study, ... access journal Genome Biology , is an Editor,s Pick. ... Texas A&M University, Miami University, and University of Arkansas scientists. ...
... of scientists from the National University of Singapore,s (NUS) Department ... drug-led compound a compound that is undergoing preclinical trials ... energy and stop them from growing into a tumour. This ... first time a research group has provided evidence showing how ...
Cached Biology News:New microscope uses rainbow of light to image the flow of individual blood cells 2New microscope uses rainbow of light to image the flow of individual blood cells 3Breast-fed babies' gut microbes contribute to healthy immune systems 2Novel discovery by NUS scientists paves the way for more effective treatment of cancers 2
... Pierce offers maleimide activated carrier proteins ... conjugates. Imject Maleimide Activated Carrier Proteins ... been preactivated with a heterobifunctional cross-linker ... stable, sulfhydryl-reactive carrier protein. Thus ...
...
... A perfect complement to high-speed analytical techniques, the AutoTrace SPE is a ... automates the cartridge conditioning, sample loading and elution steps for large volumes aqueous ... ... ...
Cell Culture Flask, 25 cm, tissue-culture treated polystyrene...
Biology Products: